* Michael Lewis: What the FCIC report should have said

* David Snow sits in on a private equity firm’s Monday morning meeting

* Morning Call: U.S. futures point higher, London opens strong, European shares climb and the Nikkei hits 9-month high.

* Chris Jones: Lara Logan’s math

* Fred Wilson comes to Harvard Business School

* MG Siegler: Is Apple’s subscription plan brilliant, brazen or batsh*t crazy?

* Still not getting Term Sheet’s morning emails? Sign up (for free) here!

* Neil Irwin: Americans are saving more and paying down debt faster than analysts had expected

* Did Barclays Capital “secretly and selfishly” manipulate the auction for Del Monte Foods (DLM)?

* SAC Capital’s Stevie Cohen opens up, albeit not about the insider trading case raging around his firm.

* Too much money chasing too few deals: Oaktree Capital hands back $3 billion of a $10 billion distressed debt fund, due to a lack of buying opportunities.

* Big deal: Genzyme (GENZ) has agreed to be acquired by Sanofi-Aventis (SNY) for $20.1 billion in cash. The $74 per share deal is about 7% higher than Sanofi’s original offer, but also well shy of the $80 per share that Sanofi may have set as a ceiling.